TY - JOUR
TI - Repeated leftover serosurvey of sars-cov-2 igg antibodies in greece, may to august 2020
AU - Bogogiannidou, Z.
AU - Speletas, M.
AU - Vontas, A.
AU - Nikoulis, D.J.
AU - Dadouli, K.
AU - Kyritsi, M.A.
AU - Mouchtouri, V.A.
AU - Mina, P.
AU - Anagnostopoulos, L.
AU - Koureas, M.
AU - Karavasilis, V.
AU - Nikou, O.
AU - Pinaka, O.
AU - Thomaidis, P.C.
AU - Kadoglou, K.
AU - Bedevis, K.
AU - Spyrou, N.
AU - Eleftheriou, A.A.
AU - Papaevangelou, V.
AU - Gikas, A.
AU - Vatopoulos, A.
AU - Ntzani, E.E.
AU - Prezerakos, P.
AU - Tsiodras, S.
AU - Hadjichristodoulou, C.
JO - Vaccine
PY - 2021
VL - 9
TODO - 5
SP - null
PB - MDPI AG
SN - 0264-410X
TODO - 10.3390/vaccines9050504
TODO - immunoglobulin G antibody;  SARS-CoV-2 antibody, adult;  aged;  Article;  case fatality rate;  chemiluminescent microparticle immunoassay;  child;  controlled study;  coronavirus disease 2019;  cross-sectional study;  female;  geographic distribution;  Greece;  human;  immune response;  infection fatality rate;  major clinical study;  male;  mortality;  nonhuman;  sensitivity and specificity;  seroepidemiology;  seroprevalence;  Severe acute respiratory syndrome coronavirus 2
TODO - A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between May and August 2020. It was designed as a cross-sectional survey and was repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Of 20,110 serum samples collected, 89 (0.44%) were found to be positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (0.35%) observed in May 2020. The highest seroprevalence was primarily observed in the “30–49” year age group. Females presented higher seroprevalence compared to males in May 2020 (females: 0.58% VS males: 0.10%). This difference reversed during the study period and males presented a higher proportion in August 2020 (females: 0.12% VS males: 0.58%). Differences in the rate of seropositivity between urban areas and the rest of the country were also observed during the study period. The four-month infection fatality rate (IFR) was estimated to be 0.47%, while the respective case fatality rate (CFR) was at 1.89%. Our findings confirm low seroprevalence of COVID-19 in Greece during the study period. The young adults are presented as the most affected age group. The loss of the cumulative effect of seropositivity in a proportion of previous SARS-CoV-2 infections was indicated. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
ER -